Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 98

1.

Prognostic role of chemotherapy-induced neutropenia in first-line treatment of advanced ovarian cancer. A pooled analysis of MITO2 and MITO7 trials.

Daniele G, Arenare L, Scambia G, Pisano C, Sorio R, Breda E, De Placido S, Savarese A, Ferrandina G, Raspagliesi F, Panici PB, Ferro A, Rimanti A, Cormio G, Lorusso D, Cecere SC, Scalone S, Marsico VA, Cardalesi C, Cognetti F, Salutari V, Attademo L, Guizzaro L, Schettino C, Piccirillo MC, Perrone F, Gallo C, Pignata S.

Gynecol Oncol. 2019 Jul;154(1):83-88. doi: 10.1016/j.ygyno.2019.04.012. Epub 2019 Apr 24.

PMID:
31029508
2.

Tolerability of PLD/oxaliplatin regimen in recurrent ovarian cancer patients with previous fragility to carboplatin/paclitaxel treatment.

Palma MD, Lombardi G, Donach ME, Borgato L, Zustovich F, Furini L, Nicoletto MO.

Am J Clin Oncol. 2011 Jun;34(3):305-8. doi: 10.1097/COC.0b013e3181e1cb22.

PMID:
20622643
3.

Chemotherapy: A new standard combination for recurrent ovarian cancer?

Bast RC Jr, Markman M.

Nat Rev Clin Oncol. 2010 Oct;7(10):559-60. doi: 10.1038/nrclinonc.2010.152. No abstract available.

4.

A randomized phase II study of carboplatin plus pegylated liposomal doxorubicin versus carboplatin plus paclitaxel in platinum sensitive ovarian cancer patients: a Hellenic Cooperative Oncology Group study.

Bafaloukos D, Linardou H, Aravantinos G, Papadimitriou C, Bamias A, Fountzilas G, Kalofonos HP, Kosmidis P, Timotheadou E, Makatsoris T, Samantas E, Briasoulis E, Christodoulou C, Papakostas P, Pectasides D, Dimopoulos AM.

BMC Med. 2010 Jan 7;8:3. doi: 10.1186/1741-7015-8-3.

5.

A Phase II clinical trial of pegylated liposomal doxorubicin and carboplatin in Japanese patients with platinum-sensitive recurrent ovarian, fallopian tube or primary peritoneal cancer.

Nakanishi T, Aoki D, Watanabe Y, Ando Y, Tomotsugu N, Sato Y, Saito T.

Jpn J Clin Oncol. 2015 May;45(5):422-6. doi: 10.1093/jjco/hyv016. Epub 2015 Feb 10.

PMID:
25670764
6.

Is chemotherapy-induced neutropenia a prognostic factor in patients with ovarian cancer?

Kim JJ, Park JY, Kim DY, Kim JH, Kim YM, Nam JH, Kim YT.

Acta Obstet Gynecol Scand. 2010 May;89(5):623-8. doi: 10.3109/00016341003674913.

PMID:
20423275
7.

Carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in partially platinum-sensitive ovarian cancer patients: results from a subset analysis of the CALYPSO phase III trial.

Gladieff L, Ferrero A, De Rauglaudre G, Brown C, Vasey P, Reinthaller A, Pujade-Lauraine E, Reed N, Lorusso D, Siena S, Helland H, Elit L, Mahner S.

Ann Oncol. 2012 May;23(5):1185-9. doi: 10.1093/annonc/mdr441. Epub 2011 Oct 5.

PMID:
21976386
9.

Decreased hypersensitivity reactions with carboplatin-pegylated liposomal doxorubicin compared to carboplatin-paclitaxel combination: analysis from the GCIG CALYPSO relapsing ovarian cancer trial.

Joly F, Ray-Coquard I, Fabbro M, Donoghoe M, Boman K, Sugimoto A, Vaughan M, Reinthaller A, Vergote I, Ferrandina G, Dell'Anna T, Huober J, Pujade-Lauraine E.

Gynecol Oncol. 2011 Aug;122(2):226-32. doi: 10.1016/j.ygyno.2011.04.019. Epub 2011 May 14.

PMID:
21575983
10.

[Combined pegylated liposomal doxorubicin and carboplatin in the treatment of recurrent epithelial ovarian cancer].

Zheng H, Gao YN, Jiang GQ, Gao M, Wang W, Yan X.

Zhonghua Fu Chan Ke Za Zhi. 2008 Nov;43(11):839-42. Chinese.

PMID:
19087568
11.

Efficacy of pegylated liposomal doxorubicin (PLD) plus carboplatin in ovarian cancer patients who recur within six to twelve months: a phase II study.

Power P, Stuart G, Oza A, Provencher D, Bentley JR, Miller WH Jr, Pouliot JF.

Gynecol Oncol. 2009 Sep;114(3):410-4. doi: 10.1016/j.ygyno.2009.04.037. Epub 2009 Jun 10.

PMID:
19520420
12.

Safety of a 3-weekly schedule of carboplatin plus pegylated liposomal doxorubicin as first line chemotherapy in patients with ovarian cancer: preliminary results of the MITO-2 randomized trial.

Pignata S, Scambia G, Savarese A, Breda E, Scollo P, De Vivo R, Rossi E, Gebbia V, Natale D, Del Gaizo F, Naglieri E, Ferro A, Musso P, D'Arco AM, Sorio R, Pisano C, Di Maio M, Signoriello G, Annunziata A, Perrone F; MITO Investigators.

BMC Cancer. 2006 Aug 1;6:202.

13.

Chemotherapy-induced neutropenia as a biomarker of survival in advanced ovarian carcinoma: an exploratory study of the gynecologic oncology group.

Tewari KS, Java JJ, Gatcliffe TA, Bookman MA, Monk BJ.

Gynecol Oncol. 2014 Jun;133(3):439-45. doi: 10.1016/j.ygyno.2014.03.013. Epub 2014 Mar 20.

14.

Ovarian cancer in elderly patients: carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in late relapse: a Gynecologic Cancer Intergroup (GCIG) CALYPSO sub-study.

Kurtz JE, Kaminsky MC, Floquet A, Veillard AS, Kimmig R, Dorum A, Elit L, Buck M, Petru E, Reed N, Scambia G, Varsellona N, Brown C, Pujade-Lauraine E; Gynecologic Cancer Intergroup.

Ann Oncol. 2011 Nov;22(11):2417-23. doi: 10.1093/annonc/mdr001. Epub 2011 Mar 14.

PMID:
21402619
15.

Topotecan plus carboplatin versus standard therapy with paclitaxel plus carboplatin (PC) or gemcitabine plus carboplatin (GC) or pegylated liposomal doxorubicin plus carboplatin (PLDC): a randomized phase III trial of the NOGGO-AGO-Study Group-AGO Austria and GEICO-ENGOT-GCIG intergroup study (HECTOR).

Sehouli J, Chekerov R, Reinthaller A, Richter R, Gonzalez-Martin A, Harter P, Woopen H, Petru E, Hanker LC, Keil E, Wimberger P, Klare P, Kurzeder C, Hilpert F, Belau AK, Zeimet A, Bover-Barcelo I, Canzler U, Mahner S, Meier W.

Ann Oncol. 2016 Dec;27(12):2236-2241. doi: 10.1093/annonc/mdw418. Epub 2016 Oct 26.

PMID:
27789470
16.

Sequential gemcitabine-carboplatin followed by paclitaxel-carboplatin in the first-line treatment of advanced ovarian cancer: A phase II study.

Mäenpää JU, Grénman SE, Jalkanen JT, Kuoppala TA, Leminen AO, Puistola US, Vuolo-Merilä PM, Yliskoski MH.

Gynecol Oncol. 2006 Apr;101(1):114-9. Epub 2005 Nov 2.

PMID:
16266743
17.

A phase II clinical trial of pegylated liposomal doxorubicin and carboplatin plus bevacizumab in patients with platinum-sensitive recurrent ovarian, fallopian tube, or primary peritoneal cancer.

del Carmen MG, Micha J, Small L, Street DG, Londhe A, McGowan T.

Gynecol Oncol. 2012 Sep;126(3):369-74. doi: 10.1016/j.ygyno.2012.05.028. Epub 2012 May 30.

PMID:
22659190
18.

Paclitaxel, carboplatin and pegylated liposomal doxorubicin in ovarian and peritoneal carcinoma: a phase I study of the Gynecologic Oncology Group.

Rose PG, Greer BE, Horowitz IR, Markman M, Fusco N.

Gynecol Oncol. 2007 Jan;104(1):114-9. Epub 2006 Sep 7.

PMID:
16959305
19.

Impact of secondary cytoreductive surgery on survival in patients with platinum sensitive recurrent ovarian cancer: analysis of the CALYPSO trial.

Lee CK, Lord S, Grunewald T, Gebski V, Hardy-Bessard AC, Sehouli J, Woie K, Heywood M, Schauer C, Vergote I, Scambia G, Ferrero A, Harter P, Pujade-Lauraine E, Friedlander M.

Gynecol Oncol. 2015 Jan;136(1):18-24. doi: 10.1016/j.ygyno.2014.09.017. Epub 2014 Oct 2.

PMID:
25281492
20.

Supplemental Content

Support Center